Eli Lilly and Company (LILY34) — Capital Reinvestment Ratio
Eli Lilly and Company (LILY34) has a Capital Reinvestment Ratio of 0.92x as of December 2025, meaning it reinvests 1% of its operating cash flow (R$3.22 Billion) in capital expenditures (R$2.97 Billion). See Eli Lilly and Company net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Eli Lilly and Company Capital Reinvestment Ratio (2014–2025)
This chart tracks Eli Lilly and Company's Capital Reinvestment Ratio across 12 annual periods. Check Eli Lilly and Company (LILY34) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Eli Lilly and Company (2014–2025)
Year-by-year Capital Reinvestment Ratio for Eli Lilly and Company from 2014 to 2025. For live market cap and broader valuation context, see Eli Lilly and Company (LILY34) total market value.
| Year | Reinvestment Ratio | Operating CF (BRL) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.65x | R$16.81 Billion | R$10.85 Billion | ▼ -32.3% |
| 2024 | 0.95x | R$8.82 Billion | R$8.40 Billion | ▼ -7.4% |
| 2023 | 1.03x | R$5.71 Billion | R$5.88 Billion | ▲ +293.1% |
| 2022 | 0.26x | R$7.08 Billion | R$1.85 Billion | ▲ +45.1% |
| 2021 | 0.18x | R$7.26 Billion | R$1.31 Billion | ▼ -42.2% |
| 2020 | 0.31x | R$6.50 Billion | R$2.03 Billion | ▲ +11.6% |
| 2019 | 0.28x | R$4.84 Billion | R$1.35 Billion | ▼ -48.8% |
| 2018 | 0.55x | R$5.52 Billion | R$3.02 Billion | ▲ +41.8% |
| 2017 | 0.39x | R$5.62 Billion | R$2.16 Billion | ▲ +71.2% |
| 2016 | 0.23x | R$4.85 Billion | R$1.09 Billion | ▼ -37.4% |
| 2015 | 0.36x | R$2.96 Billion | R$1.07 Billion | ▲ +37.9% |
| 2014 | 0.26x | R$4.46 Billion | R$1.16 Billion | — |